We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Stephen Tyring

Stephen K. Tyring MD, PhD

Clinical Professor, Departments of Dermatology, Microbiology/Molecular Genetics and Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas

Dr Stephen Tyring is a Clinical Professor in the Departments of Dermatology, Microbiology/Molecular Genetics and Internal Medicine at the University of Texas Health Science Center at Houston. Dr. Tyring is former President of the Texas Dermatological Society (2009-2010). He is board certified by the American Academy of Dermatology (AAD), and is a member of the Infectious Disease Society of America, as well as the American Federation for Clinical Research. 

Dr Tyring is an Assistant Editor for the  J Am Acad Dermatol, and sits on several editorial boards as well as serves as a reviewer for a number of journals including the N Eng J Med, Lancet, JAMA/JAMA Dermatol, J Infect Dis & Ann Intern Med.   A principal investigator for over 200 successfully completed clinical trials, Dr. Tyring’s research interests include the therapy and prevention of various mucocutaneous diseases, especially those disorders with an infectious and/or immunological basis. Dr. Tyring is the author of over 700 journal articles and book chapters as well as ten books.

Recent Contributions to PracticeUpdate:

  1. Vaccination Against HPV
  2. Intralesional Cidofovir for Treatment of Recalcitrant Warts in Both Immunocompetent and Immunocompromised Patients
  3. Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy
  4. Recalcitrant Cutaneous Warts Treated With Quadrivalent HPV Vaccine
  5. Intralesional vs Intramuscular Bivalent HPV Vaccine in the Treatment of Recalcitrant Common Warts
  6. Occurrence of Extensive Cutaneous HPV Infection After Initiation of Tofacitinib Therapy
  7. Pearls From the Fall Clinical Dermatology Meeting 2018: Update on Vaccines in Dermatology
  8. EADV 2018: HPV Vaccination Rates Are Too Low to Permanently End the Chain of Infection
  9. The 9-Valent HPV Vaccine for Treatment of Squamous Cell Carcinomas
  10. HPV-Associated Cutaneous Disease Burden in HIV-Positive Patients

Most Read This Week

Recently Updated